Craig Dietz
Internal Medicine · Kansas City, MONPI 1740247097
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $176,221 of the $226,117 with a category attached, or 77.9%. 10 manufacturers reported payments, led by Viiv Healthcare Company at 50.1% of the total. Reporting peaked in 2019 at $60,332 and has fallen 74.6% since, to $15,315 in 2025. Among internal medicine clinicians in MO with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 297 payments — averaging $761.34 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Viiv Healthcare Company$113K
- Gilead$101K
- Merck$6K
- Janssen Products, LP$3K
- Janssen Scientific Affairs, LLC$2K
- Organon$204
- plus $240 from 4 others
Across 411 payments — averaging $9278.71 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Merck$3.3M
- Gilead$349K
- AbbVie$161K
- Janssen Research & Development, LLC$29K
- Viiv Healthcare Company$2K
What the payments were for
- Consulting fees$25,36011%
- Speaking & faculty fees$176,22178%
- Travel & lodging$17,6588%
- Food & beverage$6,7773%
- Education$1000%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Viiv Healthcare Company | 85 | $113,202 |
| Gilead | 168 | $101,461 |
| Merck | 12 | $5,949 |
| Janssen Products, LP | 5 | $3,500 |
| Janssen Scientific Affairs, LLC | 1 | $1,560 |
| Organon | 7 | $204 |
| Johnson & Johnson | 16 | $193 |
| Amgen | 1 | $17 |
| Phadia US Inc. | 1 | $17 |
| Pfizer | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$226,117 in reported general payments places this provider in the 95th percentile of 2,097 internal medicine providers in Missouri.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| BiktarvyBictegrav/Emtricit/Tenofov Ala | 307 | $1,268,262 |
| SymtuzaDarunavir/Cob/Emtri/Tenof Alaf | 42 | $210,768 |
| OdefseyEmtricitab/Rilpiviri/Tenof Ala | 42 | $157,146 |
| DovatoDolutegravir Sodium/Lamivudine | 37 | $121,073 |
| JulucaDolutegravir/Rilpivirine | 32 | $113,569 |
| TivicayDolutegravir Sodium | 31 | $68,662 |
| GenvoyaElviteg/Cob/Emtri/Tenof Alafen | 12 | $48,540 |
| DescovyEmtricitabine/Tenofov Alafenam | 15 | $35,206 |
| JardianceEmpagliflozin | 38 | $33,463 |
| TrulicityDulaglutide | 18 | $26,575 |
| JanuviaSitagliptin Phosphate | 17 | $12,557 |
| OzempicSemaglutide | 11 | $12,429 |
| FarxigaDapagliflozin Propanediol | 16 | $11,026 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 27 | $3,774 |
| JanumetSitagliptin Phos/Metformin Hcl | 12 | $3,702 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GileadBiktarvy, Genvoya, Descovy | $101,461 | $1,352,007334 claims |
| Viiv Healthcare CompanyDovato, Juluca, Tivicay | $113,202 | $303,303100 claims |
| Janssen Products, LPSymtuza | $3,500 | $210,76842 claims |
| MerckJanuvia, Janumet | $5,949 | $16,25929 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,097 internal medicine providers in Missouri.
Other internal medicine in Kansas City
- Kevin SuttmoellerKansas City$198K
- Karla Houston-GrayKansas City$24K
- Kehinde MorohunfolaKansas City$16K
- David WiltKansas City$13K
- Jonathan SzetoKansas City$13K
- Timothy SmithSaint Peters$428K
- Vinay KamatSaint Louis$191K
- David PrelutskySaint Louis$182K
- Dima DandachiColumbia$157K
- Justin SteinkampSaint Charles$139K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.